The independent, non-profit HealthWell Foundation is launching a new fund dedicated to supporting patients who suffer from pulmonary fibrosis. The main mission of the foundation is to offer financial help to underinsured people in the United States in order to improve their access to life-changing medical treatments.
A phase III clinical trial sponsored by the Fundación Pública Andaluza para la gestión de la Investigación en Sevilla (FISEVI) in Spain is currently recruiting participants to enroll in a study designed to assess the efficacy of idiopathic pulmonary fibrosis (IPF) treatment, cotrimoxazole (TriSulfa-FPI). The study is entitled “…
Dr. Thomas Kuerner at Nippon Boehringer Ingelheim Co., Ltd. in Japan published a review regarding the critical rules and requirements for global clinical trials in rare lung diseases such as pulmonary fibrosis from a sponsor’s perspective. The review was published in the journal…
Researchers from Shanghai Jiao Tong University in China published in the journal BioMed Research International their findings on the mechanism behind acute lung injury and pulmonary fibrosis observed after poisoning with the chemical paraquat. The study is entitled “DNaseI Protects…
The University of Alabama at Birmingham recently reacted to news of its inclusion into the Pulmonary Fibrosis Foundation Care Center Network, stating that it is an honor in recognition of their commitment towards patients who suffer from pulmonary fibrosis (PF), and that being an official PFFCC will allow them to…
The European Commission (EC) has approved Boehringer Ingelheim‘s application for the commercialization of the drug nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF), within the European Union. Under the brand name Ofev, the drug therapy was approved by the EC due to…
Lung Institute has announced the opening of a new clinic located in Scottsdale, Arizona this February, according to a press release. The new facility will become the institute’s third center to open in the United States that is focused on treatments using stem cells, joining a center in Tampa and in Nashville.
Columbia University Medical Center and Biogen Idec have established a strategic alliance worth $30 million focused on genetic research with the purpose of discovering underlying disease causes and new therapeutic options. The collaborative program is expected to broaden the knowledge of genomics and genome sequencing, as well as help patients who…
Genkyotex, a company developing selective NOX inhibitors for the treatment of chronic diseases, has completed a $21 million Series D round of financing. The proceeds from the financing will be invested in the company’s phase 2 trial to study GKT137831, a therapy for diabetic nephropathy, a progressive fibrotic disease, as well as idiopathic…
Biopharmaceutical Bristol-Myers Squibb Company and the non-profit organization California Institute for Biomedical Research (Calibr) have established a worldwide research collaboration focused on the development of novel small molecule anti-fibrotic therapies, as well as an exclusive license agreement for the company to develop, manufacture and commercialize preclinical compounds from Calibr that result from the…
Get regular updates to your inbox.
